Safety, pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized, placebo-controlled design

Safety, pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized, placebo-controlled design

Abstract In preclinical studies, GST-HG141, a novel hepatitis B virus (HBV) capsid assembly modulator displayed potent anti-HBV activity in vitro and strong efficacy in HBV animal models. A randomized, double-blind, ascending phase 1b trial assessed the pharmacokinetics, safety, and efficacy of GST-...

Full description

Saved in:
Bibliographic Details
Main Authors: Min Wu, Jiajia Mai, Hong Zhang, George Zhang, John Mao, Yanan Tang, Wenhao Yan, Wenqiang Wu, Jinlin Hou, Xieer Liang, Zhihong Liu, Yanhua Ding, Junqi Niu
Format: Article
Language:English
Published: BMC 2024-12-01
Series:Virology Journal
Subjects:
Antiviral therapy
Hepatitis B
Pharmacokinetics
Tolerability
Capsid assembly modulator
Online Access:https://doi.org/10.1186/s12985-024-02584-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12985-024-02584-8

Similar Items